A Multiple Dose Study of MK-3614 (MK-3614-002)
Hypertension

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Has mild to moderate hypertension
- Has grade 1 or 2 arterial hypertension being treated with a single antihypertensive drug
- Has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months; or who have discontinued smoking or the use of nicotine/nicotine-containing products for at least approximately 3 months
- Is in generally good health
Exclusion Criteria:
- Has a history of clinically significant abnormalities or diseases
- Has a history of stroke, chronic seizures, or major neurological disorder
- Has a functional disability that can interfere with rising from a sitting position to the standing position
- Has any personal or family history of a bleeding or a clotting disorder
- Has a history of frequent nose bleeds or has recurrent or active gingivitis
- Has a history of cancer
- Has a history of clinically significant cardiac disease
- Is unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies approximately 2 weeks prior to the administration of study drug
- Consumes excessive amounts of alcohol
- Consumes excessive amounts of caffeinated beverages per day
- Has had major surgery, donated or lost 1 unit of blood or participated in another investigational study within 4 weeks of study
- Has a history of significant multiple and/or severe allergies (including latex) to prescription or non-prescription drugs or food
- Is currently a regular user of any illicit drugs or has a history of drug abuse within approximately 1 year
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Experimental
Experimental
Experimental
Experimental
Experimental
Placebo Comparator
MK-3614 0.25 mg (Panel A)
MK-3614 0.50/0.25 mg (Panel B)
MK-3614 0.50/0.25 mg (Panel C Repeat)
MK-3614 0.50 mg (Panel D)
MK-3614 0.50 mg (Panel E)
Placebo (All Panels)
Participants received 0.25 mg of MK-3614 twice daily (BID) every 12 hours orally for 10 days.
Participants received 0.50 mg of MK-3614 in the morning (AM) and 0.25 mg of MK-3614 in the evening (PM) 12 hours apart orally for 10 days.
Participants were to receive 0.75 mg of MK-3614 BID every 12 hours orally for 10 Days. Per protocol amendment, the Panel B dose was repeated, and participants received instead 0.50 mg of MK-3614 in the AM, and 0.25 mg of MK-3614 in the PM, 12 hours apart orally for 10 days.
Participants received 0.50 mg of MK-3614 three times a day (TID) orally every 8 hours on Day 1 followed by a wash out period for Days 2, 3 and 0.50 mg of MK-3614 every 12 hours orally for 10 days (Days 4-13).
Participants were to receive orally 0.50 mg of MK-3614 BID every 12 hours on Day 1 followed by 3 doses (0.50/0.50/0.25 mg) of MK-3614 each 8 hours apart on Day 2; three doses of 0.50 mg of MK-3614 8 hours apart on Days 3,4; and 0.75 mg of MK-3614 BID every 12 hours on Days 5-14. No participants were enrolled in this group.
Participants received a dose matched placebo orally according to randomization.